Portfolio manager comments — Q3 2025
The fund posted a positive return during the quarter, gaining approximately 0.7% in SEK, which was slightly ahead of its benchmark, the SIX SRI Nordic 200 Net Index.
Nordic markets displayed significant differences in performance, with Finland and Sweden leading the gains while Denmark lagged, partly due to the weak performance of Novo Nordisk. The continued weakness in the Nordic region’s largest company is partly attributable to heightened concerns over regulatory changes and increasing competition. In general, markets remain influenced by rising protectionism, particularly from the United States, and ongoing geopolitical uncertainty. At the same time, interest rate cuts have served as a positive factor for overall market sentiment.
In Europe, a more coordinated stance on economic stimulus has been observed, with increased infrastructure investment initiatives, including in the Nordic region. We expect these measures to have positive spillover effects on the broader economy. Currency movements were somewhat less pronounced compared to the previous quarter.
The strongest positive contributors to performance were Genmab, H&M, ABB, Hexagon, SEB, Sandvik, Swedbank, Salmar, NKT, and MOWI. The largest negative contributors were Novo Nordisk, DSV, Asker Healthcare, and Novonesis.
During the quarter, the fund added new significant positions such as Dometic, a provider of products for recreational vehicles and boats, and the Danish pharmaceutical company H. Lundbeck. Divested holdings included Orkla, SoftwareOne, F‑Secure, Kesko, and Vimian.
We have seen relatively large market swings, and this is likely to continue, which is why we maintain a broad sector exposure. Global risks persist, and we continue to prefer Nordic and European exposure within our portfolio holdings.